Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When?
作者信息
Hartung Erum A
机构信息
Division of Nephrology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, and.
Department of Pediatrics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania.
出版信息
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):11-13. doi: 10.2215/CJN.0000000000000028.
Abstract
摘要
相似文献
1
Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Children: Why, Who, and When?托伐普坦用于儿童常染色体显性多囊肾病：为何、何人及何时使用？
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):11-13. doi: 10.2215/CJN.0000000000000028.
2
Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease.托伐普坦对常染色体显性多囊肾病患者肾脏预后的剂量依赖性影响。
Kidney360. 2021 May 18;2(7):1148-1151. doi: 10.34067/KID.0007342020. eCollection 2021 Jul 29.
3
Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study.托伐普坦治疗对常染色体显性多囊肾病患者生活质量的长期影响：一项初步研究。
Clin Drug Investig. 2024 Apr;44(4):289-291. doi: 10.1007/s40261-024-01350-6. Epub 2024 Mar 2.
4
Pelvic organ prolapse in women with autosomal dominant polycystic kidney disease under tolvaptan treatment.托伐普坦治疗下常染色体显性多囊肾病女性的盆腔器官脱垂
Nefrologia (Engl Ed). 2023 Nov-Dec;43(6):791-792. doi: 10.1016/j.nefroe.2021.09.011. Epub 2023 Oct 23.
5
Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性多囊肾病患者时与总肾体积增长率无关的肾功能保存。
Clin Exp Nephrol. 2021 May;25(5):467-478. doi: 10.1007/s10157-020-02009-0. Epub 2021 Jan 20.
6
Con: Tolvaptan for autosomal dominant polycystic kidney disease-do we know all the answers?反对：托伐普坦治疗常染色体显性遗传多囊肾病——我们是否已了解所有答案？
Nephrol Dial Transplant. 2019 Jan 1;34(1):35-37. doi: 10.1093/ndt/gfy298.
7
Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.托伐普坦治疗日本晚期常染色体显性遗传性多囊肾病患者的效果。
J Nephrol. 2018 Dec;31(6):961-966. doi: 10.1007/s40620-018-0545-8. Epub 2018 Oct 24.
8
Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan.托伐普坦治疗常染色体显性遗传多囊肾病日本患者的效果：TEMPO 3:4 和 TEMPO 扩展日本研究的事后分析。
Clin Exp Nephrol. 2021 Sep;25(9):1003-1010. doi: 10.1007/s10157-021-02083-y. Epub 2021 Jun 4.
9
Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.托伐普坦治疗常染色体显性多囊肾病真实世界患者的安全性和有效性：SLOW-PKD 监测的中期结果。
Clin Exp Nephrol. 2021 Nov;25(11):1231-1239. doi: 10.1007/s10157-021-02100-0. Epub 2021 Jul 6.
10
Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations.托伐普坦对不同基因突变的常染色体显性多囊肾病患者肾脏受累的影响。
Clin Exp Nephrol. 2021 Mar;25(3):251-260. doi: 10.1007/s10157-020-01988-4. Epub 2020 Nov 3.
引用本文的文献
1
Progressive Polycystic Kidney Disease in an Infant Girl With TSC2/PKD1 Contiguous Gene Syndrome.一名患有TSC2/PKD1相邻基因综合征的女婴的进行性多囊肾病
Cureus. 2024 Aug 26;16(8):e67800. doi: 10.7759/cureus.67800. eCollection 2024 Aug.
本文引用的文献
1
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.托伐普坦治疗常染色体显性遗传多囊肾病患儿和青少年患者的随机对照试验
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):36-46. doi: 10.2215/CJN.0000000000000022.
2
Nephrogenic diabetes insipidus in children (Review).儿童肾性尿崩症（综述）
Exp Ther Med. 2021 Jul;22(1):746. doi: 10.3892/etm.2021.10178. Epub 2021 May 11.
3
Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease.常染色体显性遗传多囊肾病和常染色体隐性遗传多囊肾病进展的预测因素。
Pediatr Nephrol. 2021 Sep;36(9):2639-2658. doi: 10.1007/s00467-020-04869-w. Epub 2021 Jan 21.
4
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.托伐普坦治疗快速进展型常染色体显性多囊肾病的实用指南。
J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18.
5
Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?常染色体显性多囊肾病正在成为一种儿科疾病吗？
Front Pediatr. 2017 Dec 20;5:272. doi: 10.3389/fped.2017.00272. eCollection 2017.
6
Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.在常染色体显性多囊肾病中，基线总肾体积和肾脏生长速度与慢性肾脏病进展相关。
Kidney Int. 2018 Mar;93(3):691-699. doi: 10.1016/j.kint.2017.09.027. Epub 2017 Dec 28.
7
Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.极早发型常染色体显性多囊肾病患者的长期预后
Am J Nephrol. 2016;44(3):171-8. doi: 10.1159/000448695. Epub 2016 Aug 23.
8
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.常染色体显性遗传多囊肾病的影像学分类：一种用于选择临床试验患者的简单模型。
J Am Soc Nephrol. 2015 Jan;26(1):160-72. doi: 10.1681/ASN.2013101138. Epub 2014 Jun 5.
9
Tolvaptan in patients with autosomal dominant polycystic kidney disease.托伐普坦治疗常染色体显性遗传多囊肾病。
N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3.
10
Magnetic resonance imaging of kidney and cyst volume in children with ADPKD.磁共振成像在儿童多囊肾病中对肾脏和囊肿体积的评估。
Clin J Am Soc Nephrol. 2011 Feb;6(2):369-76. doi: 10.2215/CJN.03780410. Epub 2010 Nov 29.
Zotero 插件